Q&A on the Reverse Share Split – Biotech Investments

The market for SCLC treatments is forecasted to reach $2.3bn by 2029. Credit: Shutterstock/Anucha Tiemsom. In another win for Genprex’s Reqorsa immunogene therapy, The US

Rybrevant with chemotherapy is the first treatment to offer prolonged progression-free survival for EGFR-mutated non-small cell lung cancer (NSCLC) patients for whom prior therapy has

A study presented at the American Academy of Ophthalmology meeting examined the relationship between tear polyunsaturated fatty acids (PUFAs), eicosanoids, and dry eye symptoms. In